Allergic Asthma Clinical Trial
Official title:
First in Man Trial to Investigate Safety and Efficacy of the New IgE Adsorber
In this study patients suffering from Immunoglobulin E (IgE) mediated asthma are treated with a method, called immune apheresis, that removes IgE from blood. In order to achieve this blood is taken continuously from the patient and then separated into plasma and blood cells by centrifuge. The plasma passes the new IgE adsorber where the IgE is specifically bound. The "cleaned" plasma re-joined with the blood cells is given back to the patient. In total each patient randomized to the apheresis group will undergo 3 treatments per week (i.e. 1 cycle) every 4 weeks over a time period of 3 months, that means 9 apheresis treatments in 3 cycles in total. Study hypothesis is that the new IgE adsorber is capable of reducing IgE in plasma/serum by at least 50% measured before the first treatment in the first cycle and after the last treatment in the last treatment cycle. The new adsorber can be safely used in patients. A group of patients with conventional drug treatment and no apheresis treatment serves as control.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03850626 -
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
|
||
| Completed |
NCT02911688 -
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
|
Phase 2 | |
| Active, not recruiting |
NCT01776177 -
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
|
N/A | |
| Completed |
NCT00485576 -
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
|
Phase 2 | |
| Completed |
NCT00736801 -
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
|
N/A | |
| Completed |
NCT00515775 -
Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children
|
N/A | |
| Completed |
NCT04259164 -
Anti-inflammatory Effects Glycopyrronium
|
Phase 3 | |
| Active, not recruiting |
NCT04619017 -
Airway Immune Response to Allergens (Use Lay Language Here)
|
Phase 1 | |
| Completed |
NCT01699594 -
Change in Airway Responsiveness After Allergen Exposure
|
N/A | |
| Completed |
NCT00999466 -
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
|
Phase 2 | |
| Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
| Completed |
NCT00434434 -
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
|
Phase 2 | |
| Completed |
NCT00492076 -
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
|
Phase 4 | |
| Completed |
NCT00490425 -
Prevention of Asthma and Allergy by Probiotic Lactobacillus GG
|
Phase 4 | |
| Completed |
NCT00829179 -
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
|
Phase 3 | |
| Recruiting |
NCT04542902 -
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
|
N/A | |
| Recruiting |
NCT04109534 -
Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma
|
N/A | |
| Active, not recruiting |
NCT05186025 -
Tyrosine Allergoid Paediatric and Adult Study
|
||
| Withdrawn |
NCT03307278 -
House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance
|
N/A | |
| Enrolling by invitation |
NCT06151938 -
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
|